A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

Adding an ICI to neoadjuvant chemotherapy can improve pCR rates and may improve OS in patients with MIBC, research suggests.

The SMC has also has accepted Cladribine, also known as Mavenclad, for the treatment of relapsing-remitting multiple ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...

The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

The EMA's human medicines committee (CHMP) has backed approval of PD-L1 inhibitor Imfinzi (durvalumab) and CTLA4 inhibitor Imjudo (tremelimumab) as a first-line treatment for advanced or ...

Hutchmed's drug is also being paired with Tagrisso and AZ's PD-L1 blocker Imfinzi (durvalumab) in global registrational trials.

Small-cell lung cancer (SCLC) is one of the most lethal cancers, with patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) experiencing a median survival of just 12 months after ...

In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab ...

Novartis Canada is pleased to announce the winners of the 2025 Novartis Oncology Young Canadian Investigator Awards (NOYCIA), ...